IL-23 promotes the development of Th17 cells, which produce IL-17, shown to be a key cytokine in maintaining inflammation in psoriasis, and therapeutic inhibition of which has shown efficacy in resolving the pathological skin changes of psoriasis [108]. Here, IL17A is linked to psoriasis.